Meta-Analysis
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Jun 27, 2022; 14(6): 594-610
Published online Jun 27, 2022. doi: 10.4240/wjgs.v14.i6.594
Table 1 Characteristics of the included studies
Ref.
Study type
Country
Period
Number (URY/BB)
Gender (M/F)
Age (URY/BB)
BMI
ASA (I/II/III)
Tumor stage (I/II/III/IV)
Differentiation (H/M/L)
Matched factors1
NOS score
Chen[30], 2018RCTChina2016.5-2017.9URY 30, BB 3017/13, 16/1455.00 ± 5.40, 53.50 ± 7.5622.89 ± 4.23, 21.38 ± 2.02NR3/10/17/0, 4/12/14/05/15/10, 4/14/121, 2, 3, 4, 7, 8, 12NA
Gao and Xiang[29], 2018RetroChina2014.1-2017.1URY 26, BB 3417/9, 21/1360.61 ± 11.14, 59.72 ± 10.7921.58 ± 1.86, 21.35 ± 1.93NR0/5/14/7, 0/7/18/98/7/11, 10/11/131, 2, 3, 5, 6, 9, 10, 11, 12, 138
Li et al[32], 2017RetroChina2010.1-2016.1URY 30, BB 3321/9, 21/1252.81 ± 5.39, 52.09 ± 6.4721.66 ± 2.54, 21.81 ± 2.62NRNG8/11/11, 9/12/121, 2, 3, 5, 6, 9, 127
Ren et al[31], 2020RCTChina2015.6-2016.12URY 44, BB 4430/14, 28/1659.61 ± 11.14, 59.72 ± 10.7921.51 ± 1.86, 21.38 ± 1.93NR0/8/25/11, 0/9/23/1214/13/17, 13/14/171, 3, 5, 6, 9, 10, 11, 13NA
Wang et al[36], 2018RetroChina2015.3-2017.6URY 81, BB 5852/29, 46/1256 (30-79), 56.5 (24-77)NRNR41/20/17/0, 28/13/16/0NR1, 3, 4, 5, 6, 98
Wang et al[34], 2021RCTChina2017.1-2018.5URY 62, BB 6244/18, 44/1854.84 ± 8.31; 54.69 ± 10.0722.43 ± 3.07, 22.46 ± 3.1727/28/7, 16/41/5NGNR1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12NA
Wu et al[33], 2021RetroChina2016.1-2019.4URY 45, BB 5027/18, 31/1959.1 ± 6.2, 59.1 ± 6.323.3 ± 3.0, 23.2 ± 2.9NR45/0/0/0, 50/0/0/07/15/23, 8/19/231, 2, 3, 4, 5, 9, 10, 11, 12, 136
Zhou et al[35], 2018RetroChina2010.6-2015.4URY 36, BB 3922/14, 24/1561 ± 5, 61 ± 823 ± 3, 22 ± 421/15/0, 23/16/036/0/0/0, 39/0/0/011/16/9, 10/19/102, 3, 4, 5, 6, 9, 10, 138
Table 2 Results of risk of bias assessment (randomised controlled trials)
Ref.
Sequence generation
Allocation concealment
Blind of participant and personnel
Blind of assessment
Outcome of incomplete data
Selective report
Other bias
Chen[30], 2018LowUnclearHighUnclearLowUnclearUnclear
Ren et al[31], 2020LowUnclearUnclearUnclearLowUnclearUnclear
Wang et al[34], 2021LowLowLowUnclearLowLowUnclear
Table 3 Subgroup analysis of all the outcomes according to study type
SubgroupTypeNo. of studiesNo. of patients
Meta-analysis results
Assessment of heterogeneity
URY
BB
OR/MD (95%CI)            
P value

P value
Operative timeRCTs31361360.93 [(-5.87)-7.73]0.7900.95
Non-RCTs41821751.71 [(-7.09)-10.51]0.7000.82
Reconstruction timeRCTs292923.32 [(-3.85)-10.49]0.360.920.0005
Non-RCTs4137156-0.41 [(-3.85)-3.03]0.810.740.0009
Intraoperative blood lossRCTs31361363.87 [(-7.02)-14.75]0.490.450.16
Non-RCTs42182140.58 [(-2.60)-3.77]0.7200.91
Total number of harvested lymph nodesRCTs292920.15 [(-1.86)-2.16]0.8800.98
Non-RCTs31631471.90 [(-0.14)-3.94]0.0700.39
Time to first passage of flatus or defecationRCTs2106106-0.26 [(-0.87)-0.34]0.400.770.04
Non-RCTs5218214-0.29 [(-0.59)-0.01]0.050.560.06
Time to first solid dietRCTs14444-0.05 [(-1.14)-1.04]0.93Not applicable
Non-RCTs4173164-0.29 [(-0.53)-(-0.05)]0.0200.67
Postoperative hospitalization timeRCTs2106106-0.01 [(-0.16)-0.14)]0.8700.84
Non-RCTs5218214-0.26 [(-0.78)-0.26]0.3200.63
Reflux gastritisRCTs292920.03 (0.01-0.11)< 0.0000100.70
Non-RCTs31932090.15 (0.03-0.66)0.0100.77
Anastomotic leakageRCTs21061060.73 (0.15-3.48)0.69Not applicable
Non-RCTs31071231.16 (0.23-5.87)0.8500.85